Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
2022 · New England Journal of Medicine · 2,396 citations
https://doi.org/10.1056/nejmoa2203690
T
Toshinari Yamashita
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
268
Papers
10.9K
Citations
31
h-index
75
i10-index
Toshinari Yamashita is an academic researcher from Kanagawa Prefectural Hospital Organization. The author has contributed to research in topics: Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies. The author has an h-index of 31, co-authored 228 publications.
ORCID: 0000-0002-6479-1660Papers by this author
worksAlpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 · New England Journal of Medicine · 2,385 citations
https://doi.org/10.1056/nejmoa1813904
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
2021 · Annals of Oncology · 702 citations
https://doi.org/10.1016/j.annonc.2021.05.801
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
2020 · Annals of Oncology · 570 citations
https://doi.org/10.1016/j.annonc.2020.11.011
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer
2020 · Annals of Oncology · 177 citations
https://doi.org/10.1016/j.annonc.2020.05.001
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
2022 · Annals of Oncology · 112 citations
https://doi.org/10.1016/j.annonc.2022.03.006
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat